NCT02423343 - A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 13, 2018

Study Completion Date

July 8, 2020

Conditions

Solid TumorNon-Small Cell Lung Cancer RecurrentHepatocellular Carcinoma Recurrent

Interventions

DRUG

Galunisertib

Administered orally

DRUG

Nivolumab

Administered IV

Trial Locations (9)

Hospital Universitario 12 de Octubre, Madrid

Hospital Regional Universitario de Málaga, Málaga

University of Alabama at Birmingham Medical Center, Birmingham

University of Texas MD Anderson Cancer Center, Houston

University of California - San Diego, La Jolla

H Lee Moffitt Cancer Center, Tampa

Dana Farber Cancer Institute, Boston

Hospital Universitari Vall d'Hebron, Barcelona

Institut Catala d'Oncologia, Barcelona